Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Common Equity (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Common Equity for 11 consecutive years, with -$126.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 1755.92% to -$126.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$126.2 million through Dec 2025, down 1755.92% year-over-year, with the annual reading at -$126.2 million for FY2025, 1755.92% down from the prior year.
  • Common Equity for Q4 2025 was -$126.2 million at Cartesian Therapeutics, down from -$35.8 million in the prior quarter.
  • The five-year high for Common Equity was $93.8 million in Q4 2022, with the low at -$440.2 million in Q4 2023.
  • Average Common Equity over 5 years is -$17.3 million, with a median of -$3.4 million recorded in 2021.
  • The sharpest move saw Common Equity skyrocketed 2222.36% in 2022, then crashed 4866.49% in 2025.
  • Over 5 years, Common Equity stood at $22.5 million in 2021, then soared by 316.62% to $93.8 million in 2022, then crashed by 569.14% to -$440.2 million in 2023, then soared by 98.45% to -$6.8 million in 2024, then plummeted by 1755.92% to -$126.2 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$126.2 million, -$35.8 million, and -$2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.